Gilead Sciences (GILD) Other Non-Current Liabilities (2009 - 2026)
Gilead Sciences' (GILD) quarterly Other Non-Current Liabilities came in at $918.0 million in Q1 2026, down 31.34% YoY from $1.3 billion in Q1 2025, and down 21.2% on a QoQ basis from $1.2 billion in Q4 2025.
Gilead Sciences (GILD) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Other Non-Current Liabilities data on file, last reported at $918.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 31.34% year-over-year to $918.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $918.0 million (down 31.34% YoY) and the FY2025 annual result came in at $1.2 billion, down 10.04% from the prior year.
- Other Non-Current Liabilities eased to $918.0 million in Q1 2026, from $1.2 billion in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.9 billion in Q2 2022 to a low of $738.0 million in Q2 2024.
- A 5-year average of $1.4 billion and a median of $1.3 billion in 2023 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 176.83% in 2022, down 76.17% in 2022.
- Tracing GILD's Other Non-Current Liabilities over 5 years: stood at $1.2 billion in 2022, then jumped by 72.94% to $2.0 billion in 2023, then sank by 36.49% to $1.3 billion in 2024, then slipped by 10.04% to $1.2 billion in 2025, then retreated by 21.2% to $918.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $918.0 million (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Bn |
| Mar 31, 2026 | 918.00 Mn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | 1.18 Bn |
| Jun 30, 2025 | 859.00 Mn |
| Mar 31, 2025 | 1.34 Bn |
| Dec 31, 2024 | 1.30 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Jun 30, 2024 | 738.00 Mn |
| Mar 31, 2024 | 1.40 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Sep 30, 2023 | 2.09 Bn |
| Jun 30, 2023 | 1.35 Bn |
| Mar 31, 2023 | 1.28 Bn |
| Dec 31, 2022 | 1.18 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 3.89 Bn |
| Mar 31, 2022 | 944.00 Mn |
| Dec 31, 2021 | 4.77 Bn |
| Sep 30, 2021 | 4.64 Bn |